Background: Treatment after failure of 2 nd line chemotherapy in patients with Hodgkin's lymphoma (HL) or aggressive non-Hodgkin's lymphoma (NHL) is not well studied. Aim: To assess the value of 3 rd line treatment in a cohort of HL and aggressive NHL patients. Methods: This was a retrospective study of patients with relapsed/refractory HL or aggressive NHL treated with 3 rd line treatment based on physician choice. Response rate as well as overall survival (OS) and factors affecting it were assessed. Results: Fifteen (41%) out of 37 patients who failed 2 nd line received 3 rd line. The remaining 22 received single-agent palliative chemotherapy or best supportive care only. Third line treatment was IGEV (ifosfamide, gemcitabine, navelbine) in 7 (47%) patients, lenalidomide in 4 (26%), ESHAP (etoposide, methylprednisolone, cytosine arabinoside, cisplatin) in 2 (13%) and GEMOX (gemcitabine, oxaliplatin) in 2 (l3%). Four (27%) patients achieved complete remission (2 with IGEV and 2 with lenalidomide) and 3 of them underwent autologous stem cell transplantation. One (7%) patient achieved partial response and another one (7%) had stable disease. The median OS for the whole group was 4.7 months. For patients who received 3 rd line the OS was significantly longer than those who didn't (13.4 vs. 3.4 months, p=0.001). Among the whole set of patients, performance status, lactate dehydrogenase, tertiary age-adjusted International Prognostic Index, 3 rd line treatment, response to 3 rd line and transplantation had significant impact on OS. Conclusion: Third line treatment may be feasible in selected HL and aggressive NHL patients who failed 2 nd line.
INTRODUCTION
Second line chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care treatment for diffuse large B-cell lymphoma and Hodgkin's lymphoma (HL) patients who failed first line treatment 1, 2 . The value of treatment of patients failing 2 nd line is not well studied.
Van Den Neste et al studied the outcome of 203 patients who failed 2 nd line treatment after the CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma) study 3, 4 . The median overall survival (OS) for the whole group in their study was 4.4 months. However, patients who received 3 rd line achieved high overall response rate (39%) with a complete response rate of 27%. Multivariate analysis showed that tertiary international prognostic index (IPI) >2 and transplantation achievement were associated with better OS (p< 0.0001 and = 0.0002, respectively) 3 . Other smaller studies like that of Elstrom et al reported the outcome of 27 patients who failed 2 nd line. The median OS for the whole group was 4 months. However, median OS for patients who received 3 rd line was much better (10 months) 5 . Seshadri et al also reported the outcome of 120 patients after failure of 2 nd line platinum-based chemotherapy. Seventy-three of them received 3 rd line with low response rate of 14% 6 . The response rate was higher (52% overall response rate and 14% complete remission) in the study of Simpson et al that included 21 patients treated with ICE (ifosfamide, carboplatin, etoposide) after failure of 2 nd line DHAP (dexamethasone, high-dose cytarabine and cisplatin) 7 . The aim of this retrospective study was to report the outcome of treatment with 3 rd line in a cohort of patients with relapsed/refractory HL and aggressive nonHodgkin's lymphoma (NHL) who failed 2 nd line treatment.
METHODS
The original study of 2 nd line chemotherapy was a prospective study that included 41 patients with relapsed/ refractory HL or aggressive NHL randomized between either GEMOX (gemcitabine, oxaliplatin) or ESHAP (etoposide, methylprednisolone, cytosine arabinoside, cisplatin). 8 During follow up that continued until May 2017, 37 out of those 41 patients failed treatment and represent the population of the current study.
The . Patients who achieved complete remission in response to 3 rd line were scheduled to undergo autologous stem cell transplant (ASCT).
Response assessment was done clinically with each cycle and by computerized tomography scan after 3 cycles and bone marrow biopsy was repeated if it was abnormal before starting treatment. Overall survival (OS) was calculated as the time from the date of failure to 2 nd line until death. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
SPSS software (statistical package for social science) version 17 was used for statistical analysis. All data statistically studied by descriptive analysis. Survival analysis was done according to possible prognostic factors by Kaplan-Meier method and compared by logrank test for significance. All reported p values are twosided, and P <0.05 was considered significant. Out of 37 patients who failed 2 nd line chemotherapy 15 (40.5%) patients received 3 rd line treatment. IGEV (ifosfamide, gemcitabine, navelbine) was the most commonly used regimen (in 7 [47%] patients). Other treatment regimens used were lenalidomide in 4 (26%) patients, ESHAP (etoposide, methylprednisolone, cytosine arabinoside, cisplatin) in 2 (13%) and GEMOX (gemcitabine, oxaliplatin) in 2 (13%). The total number of cycles was 62 and the median number per patient was 4 (range: 3-8). The remaining 22 patients received palliative single agent chemotherapy or best supportive care only.
RESULTS

During
Four (26.6%) patients achieved complete remission with 3 rd line treatment (2 with IGEV and 2 with lenalidomide) and 3 of them underwent ASCT while the 4 th lost to follow up. One (6.6%) patient achieved PR and another one (6.6%) had stable disease. Disease progression was observed in 9 (60.2%) patients.
Median OS was 4.7 months (95% Confidence Interval: 2.1-7.2) for the all patients who failed 2 nd line (figure 1) and the 1-year survival rate was 37%. The median OS was significantly longer in patients who receive 3 rd line treatment compared to those who received best supportive care (13.4 vs. 3.4 months, p=0.001) (figure 2). Other variables that correlated significantly with the OS of the whole group in univariate analysis included ECOG performance status, LDH, and tertiary aaIPI , response to 3 rd line and transplantation (table 2) .
DISCUSSION
Aggressive NHL and HL failing 2 nd line chemotherapy have very poor prognosis and represent a challenge for clinicians.
The largest data about the value of 3 rd line comes from the analysis of patients failing 2 nd line in the CORAL study 3 . In our study patients who achieved complete remission/partial remission after 3 rd line had a better median OS (not reached) in comparison to those who had stable disease/progressive disease (5.4 months). Also, patients who underwent ASCT had a better median OS (not reached) than those who did not (3.7 months).
Two patients treated with lenalidomide as 3 rd line achieved complete remission and one of them underwent ASCT. In a relatively large international phase II study; 217 patients with relapsed or refractory diffuse large Bcell lymphoma, mantle cell lymphoma, follicular grade 3 lymphoma, or transformed lymphoma received lenalidomide single agent. The overall response rate was 35% with 13% complete remission. The median response duration was 10.6 months for 77 responsive patients and it was not reached for the 29 patients who achieved complete remission 10 . Lenalidomide looks promising in this setting.
A limitation of the current study is that rituximab ,which changed significantly CD-20 positive NHL map both in 1 st and 2 nd line treatment, was not given due to logistic and financial reasons. Other limitations included being a retrospective design and the inclusion of small number of patient. Another important limitation is that molecular subtyping for cell of origin, which is an important independent prognostic factor in relapsed/ refractory diffuse large B-cell lymphoma 11 , was not performed.
Conclusion
Third line treatment is feasible in selected relapsed/refractory HL and aggressive NHL patients. The current study suggests some prognostic factors for overall survival in 3 rd line treatment as ECOG performance status, LDH, tertiary aaIPI, response to 3 rd line and transplantation.
